Literature DB >> 26196445

Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans is Associated With Nonalcoholic Fatty Liver Disease.

Sahil Mittal1, Hashem B El-Serag2, Yvonne H Sada3, Fasiha Kanwal2, Zhigang Duan4, Sarah Temple4, Sarah B May4, Jennifer R Kramer4, Peter A Richardson4, Jessica A Davila4.   

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) can develop in individuals without cirrhosis. We investigated risk factors for development of HCC in the absence of cirrhosis in a U.S.
METHODS: We identified a national cohort of 1500 patients with verified HCC during 2005 to 2010 in the U.S. Veterans Administration (VA) and reviewed their full VA medical records for evidence of cirrhosis and risk factors for HCC. Patients without cirrhosis were assigned to categories of level 1 evidence for no cirrhosis (very high probability) or level 2 evidence for no cirrhosis (high probability), which were based on findings from histologic analyses, laboratory test results, markers of fibrosis from noninvasive tests, and imaging features.
RESULTS: A total of 43 of the 1500 patients with HCC (2.9%) had level 1 evidence for no cirrhosis, and 151 (10.1%) had level 2 evidence for no cirrhosis; the remaining 1203 patients (80.1%) had confirmed cirrhosis. Compared with patients with HCC in presence of cirrhosis, greater proportions of patients with HCC without evidence of cirrhosis had metabolic syndrome, nonalcoholic fatty liver disease (NAFLD), or no identifiable risk factors. Patients with HCC without evidence of cirrhosis were less likely to have abused alcohol or have hepatitis C virus infection than patients with cirrhosis. Patients with HCC and NAFLD (unadjusted odds ratio, 5.4; 95% confidence interval, 3.4-8.5) or metabolic syndrome (unadjusted odds ratio, 5.0; 95% confidence interval, 3.1-7.8) had more than 5-fold risk of having HCC in the absence of cirrhosis, compared with patients with HCV-related HCC.
CONCLUSIONS: Approximately 13% of patients with HCC in the VA system do not appear to have cirrhosis. NAFLD and metabolic syndrome are the main risk factors for HCC in the absence of cirrhosis.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fatty Liver; Liver Cancer; NASH; Steatosis

Mesh:

Year:  2015        PMID: 26196445      PMCID: PMC4690789          DOI: 10.1016/j.cgh.2015.07.019

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  30 in total

Review 1.  Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.

Authors:  George V Papatheodoridis; Pietro Lampertico; Spilios Manolakopoulos; Anna Lok
Journal:  J Hepatol       Date:  2010-04-27       Impact factor: 25.083

2.  Liver biopsy.

Authors:  Don C Rockey; Stephen H Caldwell; Zachary D Goodman; Rendon C Nelson; Alastair D Smith
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

3.  Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.

Authors:  Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Hoi-Yun Chan; Pete Chi-Hang Tse; Yee-Kit Tse; Christy Wing-Hin Mak; Stanley King-Yeung Lee; Zoe Man-Yi Ip; Andrew Ting-Ho Lam; Henry Wing-Hang Iu; Joyce May-Sum Leung; Vincent Wai-Sun Wong
Journal:  Gastroenterology       Date:  2013-02-12       Impact factor: 22.682

4.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.

Authors:  Mustafa S Ascha; Ibrahim A Hanouneh; Rocio Lopez; Tarek Abu-Rajab Tamimi; Ariel F Feldstein; Nizar N Zein
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

6.  Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.

Authors:  Manal M Hassan; Steven A Curley; Donghui Li; Ahmed Kaseb; Marta Davila; Eddie K Abdalla; Milind Javle; Dalia M Moghazy; Richard D Lozano; James L Abbruzzese; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2010-04-15       Impact factor: 6.860

7.  Population-based risk factors and resource utilization for HCC: US perspective.

Authors:  A Sanyal; A Poklepovic; E Moyneur; V Barghout
Journal:  Curr Med Res Opin       Date:  2010-09       Impact factor: 2.580

8.  Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers.

Authors:  Matthew M Yeh; Hubert Darius-J Daniel; Michael Torbenson
Journal:  Mod Pathol       Date:  2009-11-20       Impact factor: 7.842

Review 9.  Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal.

Authors:  Franco Trevisani; Marta Frigerio; Valentina Santi; Alice Grignaschi; Mauro Bernardi
Journal:  Dig Liver Dis       Date:  2009-10-13       Impact factor: 4.088

10.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

View more
  180 in total

1.  Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis?

Authors:  M Balakrishnan; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2018-02       Impact factor: 8.171

Review 2.  Non-alcoholic fatty liver disease.

Authors:  James Maurice; Pinelopi Manousou
Journal:  Clin Med (Lond)       Date:  2018-06       Impact factor: 2.659

Review 3.  Nonalcoholic Fatty Liver Disease and Recent Guideline Updates.

Authors:  Yumi Ando; Janice H Jou
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 4.  Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer.

Authors:  Kara Wegermann; Jeongeun Hyun; Anna Mae Diehl
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 5.  NASH: The Emerging Most Common Form of Chronic Liver Disease.

Authors:  Meron Tesfay; W Joseph Goldkamp; Brent A Neuschwander-Tetri
Journal:  Mo Med       Date:  2018 May-Jun

6.  Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth.

Authors:  Clara E Dismuke-Greer; Wing-Kin Syn
Journal:  Dig Dis Sci       Date:  2019-03       Impact factor: 3.199

Review 7.  The Effects of Physical Exercise on Fatty Liver Disease.

Authors:  Dirk J van der Windt; Vikas Sud; Hongji Zhang; Allan Tsung; Hai Huang
Journal:  Gene Expr       Date:  2017-12-06

Review 8.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

9.  Lipid droplets disrupt mechanosensing in human hepatocytes.

Authors:  LiKang Chin; Neil D Theise; Abigail E Loneker; Paul A Janmey; Rebecca G Wells
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-05-28       Impact factor: 4.052

10.  Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.

Authors:  Fasiha Kanwal; Jennifer R Kramer; Srikar Mapakshi; Yamini Natarajan; Maneerat Chayanupatkul; Peter A Richardson; Liang Li; Roxanne Desiderio; Aaron P Thrift; Steven M Asch; Jinna Chu; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2018-08-23       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.